Hi @Rewop. I don’t think this has played out as any MSB shareholder would have thought. GVHD for example, I think different rules or a new vibe came into play. Out of MSBs & SI’s control. In hindsight maybe some things could have been done differently but then this is all such new medicine and if it is such a paradigm shift, perhaps the process to FDA approval also requires a paradigm shift.
I personally think SI is not your average CEO in that money is not his top priority; that doesn’t mean he does not know the value of money. Some people in officialdom may not fully appreciate this in a CEO.
Moving forward, I agree with you that a partnership with a company such as Novartis can only add insight & management expertise.
Hi @Rewop. I don’t think this has played out as any MSB...
-
- There are more pages in this discussion • 10,014 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.010(0.91%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.11 | $1.07 | $4.794M | 4.399M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14500 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 141676 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |